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ABSTRACT: The Fanconi anemia pathway orchestrates the
repair of DNA interstrand cross-links and stalled replication
forks. A key step in this pathway is UBE2T and FANCL-
dependent monoubiquitylation of the FANCD2-FANCI
complex. The Fanconi anemia pathway represents an attractive
therapeutic target, because activation of this pathway has been
linked to chemotherapy resistance in several cancers. However,
to date, very few selective inhibitors of ubiquitin conjugation
pathways are known. By using a high-throughput screen-
compatible assay, we have identified a small-molecule inhibitor
of UBE2T/FANCL-mediated FANCD2 monoubiquitylation that sensitizes cells to the DNA cross-linking agent, carboplatin.
Ubiquitylation is a post-translational modification thatregulates a myriad of cellular processes. Proteins are
ubiquitylated via an enzymatic cascade composed of E1
activating, E2 conjugating, and E3 ligating enzymes.1 Because
of the crucial physiological role of the ubiquitin system, its
dysregulation is implicated in a growing number of human
pathologies, including several cancers, developmental defects,
immunodeficiencies, and neurodegenerative disorders.2 Ubiq-
uitylation is known to play key roles in a vast array of
proteolytic and nonproteolytic regulatory mechanisms. One
area in particular where ubiquitylation events are highly
prevalent is in the DNA damage response (DDR).3
Genome integrity is continuously under attack from a
barrage of exogenous and endogenous genotoxic agents such as
ionizing radiation, ultraviolet light (UV) radiation and
oxidative stress, and by errors in DNA replication itself.
Fortunately, cells possess highly efficacious mechanisms
collectively known as the DDRwhich are able to, among
other things, detect DNA lesions, activate cell cycle
checkpoints, and repair the damaged DNA.4
The Fanconi anemia (FA) pathway, also known as the FA/
BRCA pathway, is required for the repair of DNA interstrand
cross-links (ICLs).5 ICLs are among the most cytotoxic forms
of DNA lesion, and occur when bases from opposite DNA
strands become covalently attached to each other. ICLs inhibit
essential processes such as replication and transcription and
must be repaired or bypassed for the cell to survive.
ICL-inducing anticancer agents, such as platinum-based
compounds (including cisplatin and carboplatin) and
mitomycin C, have long been used in the clinic to treat a
range of malignancies including testicular, ovarian, head and
neck, colorectal, bladder, and lung cancers.6 Although these
chemotherapies are generally initially effective at cytoreduc-
tion, tumor recurrence and drug resistance commonly arise.7
Activation or upregulation of the FA pathway has been linked
to chemotherapy resistance in several cancers; therefore, its
inhibition is hypothesized to restore sensitivity to ICL-
inducing agents.8
Currently, 22 genes are annotated as FA genes (FANCA to
FANCW; http://www2.rockefeller.edu/fanconi/mutate/),
with inactivation of any of these genes causing the genetic
cancer predisposition syndrome termed Fanconi anemia.9 Key
components of the FA pathway are the ubiquitin E2 enzyme,
UBE2T (also known as FANCT) and the RING-type ubiquitin
E3 ligase, FANCL.10 In response to the stalling of replication
forks at sites of DNA ICLs, UBE2T functions with FANCL
and the multiprotein FA complex to monoubiquitylate both
subunits of the heterodimeric FANCD2-FANCI (ID)
complex. The monoubiquitylated ID complex is then recruited
to and retained at sites of ICL lesions and provides a platform
for coordinating DNA repair events. When the repair process is
completed, the ID complex is deubiquitylated and dissociated
from the repaired ICL site by the USP1-UAF1 complex and
released from the DNA.11
Ubiquitin conjugation is dependent on many protein−
protein interactions (PPIs), and the efficient formation and
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disassociation of protein complexes. Therefore, despite
ubiquitin conjugating proteins possessing enzymatic activity,
it is perhaps more apt to classify them as PPI targets. In drug
and chemical probe discovery, such targets are viewed as
challenging. This is perhaps reflected by the scarcity of
selective small molecule inhibitors of ubiquitin conjugation
pathways reported to date.12
To identify small-molecule inhibitors of the FA pathway, we
developed a high-throughput screen (HTS) compatible assay
based on the FA ubiquitylation cascade (see Figure 1a, as well
as Figure S1 in the Supporting Information). Given the
complexity of the full FA ubiquitylation cascade, we
constructed a simplified ubiquitylation reaction that would
be robust for HTS purposes yet still provide many relevant
protein species for small molecules to interact with. The
recombinant protein assay developed used homogeneous time-
resolved fluorescence (HTRF) and contained Cy5-labeled
ubiquitin, the E1 enzyme UBE1, the E2 enzyme UBE2T, and
the RING domain (residues 275−375) of the E3 FANCL
(FANCLRING). FANCLRING was used as a surrogate substrate
for ubiquitylation in the absence of the FA core and
FANCD2/FANCI complexes.
Subsequent screening of a leadlike diversity chemical library
consisting of ∼10 000 compounds (n = 2) (robust Z score of
>0.75) (Figure S2 in the Supporting Information) at a
concentration of 20 μM led to the identification of 120
primary hits, a hit rate of 1.17% (Figure 1b). The primary hit
significance threshold (15% inhibition) was defined as three
standard deviations above the mean inhibition across the entire
screen. The compound library screened was specifically
curated to avoid compounds with known promiscuous
mechanisms of action, such as redox cycling and cysteine
reactivity.
Of the primary hits, the 32 most potent compoundsin
relation to the observed percentage inhibition at 20 μMwere
selected for a 10-point dose−response study. Of the 32
compounds tested, 12 exhibited an IC50 value of <100 μM.
Fresh stocks of these compounds were sourced from
commercial vendors and IC50 values of <100 μM were
obtained for 10 compounds (Figure S3; see the example for
CU2 in Figure S4 in the Supporting Information). For most
compounds, there was a good correlation between the data
from the primary screen and the resupplied compounds (Table
S1 in the Supporting Information).
The 10 compounds confirmed by dose−response were then
tested in an orthogonal assay to rule out interference with the
HTRF assay format. Thus, a modified ubiquitylation reaction
was run with biotinylated ubiquitin and in the absence of the
anti-GST-Tb antibody. The reaction components were then
separated by SDS-polyacrylamide gel electrophoresis and
immunoblotted. Notably, no ubiquitylation of FANCLRING
was observed in the presence of compounds CU1, CU2,
CU9, CU10, or CU12 at 100 μM, as indicated by the absence
of the band corresponding to monoubiquitylated (mUb)-GST-
FANCLRING (Figure 2a, top panel). However, CU10 and
CU12 also prevented the ubiquitylation of UBE2T (Figure S5
in the Supporting Information) and, in addition, somewhat
impaired the autoubiquitylation of UBE1 (Figure 2a, bottom
panel). Encouragingly, CU1, CU2, and CU9 did not affect
ubiquitylation of either UBE2T or UBE1 (see Figure 2a, as
well as Figure S5), thereby suggesting some target selectivity.
In order to explore the selectivity of CU1, CU2, CU9,
CU10, and CU12, we conducted a counter-screen against
other E2 and E3 combinations. Since members of the UBE2D
family of E2s are known to ubiquitylate multiple substrates in
vitro,13 a ubiquitylation assay featuring UBE2D1 and GST-
FANCLRING was performed. With UBE2D1, multiple ubiq-
uitylated GST-FANCLRING species could be observed (Figure
2b). As with UBE2T and GST-FANCLRING, CU1, CU2, CU9,
CU10, and CU12 essentially abolished the ubiquitylation of
GST-FANCLRING. CU10 and CU12 also prevented the
formation of any ubiquitylated UBE2D1 species.
A further ubiquitylation assay was performed with an
alternative E3, RNF8, which also plays important roles in the
DDR.14 In contrast to GST-FANCLRING, long polyubiquitin
chains were attached to GST-RNF8 by UBE2D1 (Figure 2c).
Consistent with our previous observations, CU10 and CU12
appeared to inhibit the ubiquitylation of all species in the assay.
In support of our data indicating the selectivity of CU 1, CU2,
and CU9, these compounds had no detectable effects on
ubiquitylation of GST-RNF8 and UBE2D1.
The lack of an inhibitory effect on the ubiquitylation of
UBE1, UBE2T, UBE2D1, and RNF8 by CU1, CU2, and CU9
suggested that these compounds bind to a specific species in
the ubiquitylation reactions and are not acting via a pan-assay
interference (PAIN)-type mechanism. Furthermore, CU1,
CU2, and CU9 appeared to exhibit some degree of selectivity
for FANCL-dependent ubiquitylation, although not necessarily
selectivity for a particular E2. We did not observe binding of
CU2 to UBE2T by differential scanning fluorimetry, ligand-
observed NMR, or native mass spectrometry (unpublished
data). Taken together, these findings suggest that the target for
CU1, CU2, and CU9 is potentially the RING domain of
Figure 1. Screening for inhibitors of the FA pathway. (a) Schematic
of the HTRF ubiquitylation assay. Ubiquitylation of GST-tagged E3
(FANCLRING) by the E2 (UBE2T) places Cy5-labeled ubiquitin in
close proximity to the anti-GST Tb cryptate. Excitation of the Tb
cryptate donor results in FRET to the Cy5 acceptor. Simultaneous
monitoring of the donor emission (620 nm) and acceptor emission
(665 nm) allows for determination of the 665/620 ratio. (b) HTRF
screen results showing average inhibition (n = 2) produced by
compounds at 20 μM (in-house diversity library; 10 111 compounds)
and 10 μM (Selleckchem epigenetic library; 119 compounds).
Numbers given in parentheses represent the number of compounds
per inhibition threshold.
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FANCL or a protein complex comprised thereof; however,
further experimental evidence will be required to confirm this.
Next, CU1, CU2, and CU9 were evaluated for their ability
to inhibit FANCL-dependent ubiquitylation events in cells.
CU10 and CU12 were deprioritized for cellular evaluation due
to their lack of selectivity in the in vitro gel-based
ubiquitylation assays. The only known in vivo function of
UBE2T and FANCL is their direct role in the monoubiqui-
tylation of the heterodimeric FANCD2-FANCI complex,
which occurs in response to certain types of DNA damage.
Hydroxyurea (HU) is a potent inhibitor of the enzyme
ribonucleotide reductase (RNR) and is an antineoplastic drug
used in the clinic.15 Inhibition of RNR limits de novo dNTP
synthesis, causing depletion of cellular dNTP pools, which, in
turn, leads to stalled and collapsed replication forks and cell
cycle arrest in S-phase. Because of the role of the FA pathway
in the stabilization and repair of stalled and collapsed
replication forks, HU is a strong inducer of the UBE2T and
FANCL-dependent monoubiquitylation of FANCD2 (mUb-
FANCD2).16
U2OS cells were treated with HU and the formation of
mUb-FANCD2 in the presence of CU 1, CU2, and CU9 was
evaluated relative to a DMSO control. Following a 1-h
preincubation with the compounds, cells were treated with 2.5
mM of HU for 24 h. Biochemically, at 100 μM, CU 1, CU2,
and CU9 completely inhibited the ubiquitylation of GST-
FANCLRING. However, consistent with the decrease in potency
often observed in cellular assays, relative to in vitro biochemical
assays,17 when cells were treated with CU 1, CU2, and CU9 at
100 μM, no significant decrease in the level of mUb-FANCD2
was observed (see Figure S6 in the Supporting Information).
Accordingly, cells were treated with a higher concentration of
compounds in further experiments. In these studies, we also
decreased the assay time from 24 h to 8 h to mitigate potential
compound instability. Thus, we found that cells tolerated CU2
and CU9 at 500 μM, while CU1 was found to be cytotoxic
above 300 μM. Notably, both CU1 (200 μM) and CU2 (500
μM) reduced the level of mUb-FANCD2 in response to HU
treatment (see Figures 3a and 3b). CU2 (500 μM) also
reduced the level of mUb-FANCD2 generated in response to
cisplatin (10 μM) treatment for 6, 12, and 24 h (Figure 3c).
Figure 2. Gel-based ubiquitylation assays with confirmed HTRF hits. CU1, CU2, and CU9 inhibit the ubiquitylation of GST-FANCLRING, but not
GST-RNF8. Western blots (WB) probed for GST or biotin as labeled. Reactions contained 20 nM His6-UBE1, 50 nM E2, 250 nM GST-E3, 500
nM biotinylated ubiquitin: (a) E2 = UBE2T, E3 = GST-FANCLRING, 30 min of reaction at 37 °C; (b) E2 = UBE2D1, E3 = GST-FANCLRING, 30
min of reaction at 37 °C; and (c) E2 = UBE2D1, E3 = GST-RNF8, 10 min of reaction at 37 °C.
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As DNA damage induced by HU is cell-cycle-dependent, it
was necessary to establish whether CU1 and CU2 might
simply prevent cells from entering the S-phase, which would
also manifest itself as a reduction in mUb-FANCD2. This was
Figure 3. Cell-based assays with CU1 and CU2: (a) Western blot showing that the formation of mUb-FANCD2(*), in response to HU treatment
(2.5 mM, 8 h), is impaired in U2OS cells in the presence of CU1 (200 μM) or CU2 (500 μM). Ratio = mUb-FANCD2/FANCD2 (normalized to
DMSO control). mUb-FANCD2 was resolved on a separate gel. PARP1 was used as a loading control for each gel, as well as to assess apoptosis.
(b) Quantification of the reduction in mUb-FANCD2, in response to HU treatment (2.5 mM, 8 h) in the presence of CU1 (200 μM) or CU2 (500
μM). Mean calculated from three independent experiments. (c) Western blot showing that formation of mUb-FANCD2 (denoted by an asterisk
symbol, *) in response to cisplatin treatment (10 μM) for 6, 12, and 24 h is impaired in U2OS cells in the presence of CU2 (500 μM). Ratio =
mUb-FANCD2/FANCD2 (normalized to DMSO control). (d) Cell cycle analyses based upon EdU incorporation in cells treated with HU (2.5
mM, 8 h) in the presence or absence of CU1 (200 μM) or CU2 (500 μM). HU treatment was used for gating purposes. (e) Western blot showing
that CU1 (200 μM) or CU2 (500 μM) do not affect total protein ubiquitylation with or without HU treatment (2.5 mM, 8 h), as assessed by
probing with the FK2 antibody.
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determined by analysis of several biomarkers linked to DNA
damage in cycling cells. Activated CHK1 (pS345 CHK1)
phosphorylates CDC25A, inducing the transient arrest of cells
in the S-phase, or in G2 before the onset of mitosis.18
Comparable levels of pS345 CHK1 were observed in cells
treated with either CU1 or CU2, relative to the DMSO
control, indicating that the compounds were not preventing
cells from entering the S-phase (Figure 3a). These
observations were also confirmed by cell cycle analysis.
However, a slightly lower EdU (5-ethynyl-2′-deoxyuridine)
incorporation intensity, but not S-phase index, was observed
following CU1 treatment, suggesting that it may slow
progression through the S-phase (Figure 3d).
Following the generation of DNA DSBs, ATM, ATR, and/or
DNA-PKcs mediated phosphorylation of histone H2AX
generates the phosphorylated species, γH2AX.19 In accord
with our conclusion that CU1 and CU2 did not markedly
affect progression of cells into and through the S-phase, when
used to treat cells in combination with HU, CU1 or CU2 did
not decrease and, in fact, somewhat increased the levels of
γH2AX, relative to cells treated with HU plus DMSO control
(Figure 3a). Furthermore, these increased levels of γH2AX
suggested that larger numbers of DSBs were generated in HU-
treated cells incubated with CU1 or CU2, compared with cells
treated with HU and DMSO. Following HU treatment, DSBs
are formed if stalled replication forks are not stabilized and
subsequently collapse. Therefore, we concluded that CU1 and
CU2 appeared to act by impairing the ability of cells to
stabilize and repair stalled replication forks. This is consistent
with CU1 and CU2 inhibiting the formation of mUb-
FANCD2, which would otherwise play a role in stabilizing
stalled replication forks, thus preventing their collapse and the
formation of DSBs.
In response to DSB formation, the transcriptional repressor
and RING finger protein, KAP1, is released from chromatin,
following its ATM-mediated phosphorylation on Ser824.20 In
agreement with our findings with γH2AX, increased levels of
pS824 KAP1 were observed with both CU1 and CU2, which
provides further evidence of the existence of more DSBs/
collapsed replication forks (Figure 3a). An increase in the
Figure 4. Further cell-based assays with CU1 and CU2: (a, b) Representative immunofluorescence images of U2OS cells treated with HU (2.5
mM, 8 h) or cisplatin (10 μM, 8 h) in the presence or absence of CU1 (200 μM) or CU2 (500 μM). (c) Quantification of the number of FANCD2
foci in cells treated as in panels (a) and (b). Data accumulated over three independent experiments, each consisting of three technical replicas. (d)
IncuCyte analysis of U2OS cells treated with or without carboplatin (15 μM) and CU2 (250 μM). Mean calculated from three wells, four images
per well. (HU = DMSO + HU, cisplatin = DMSO + cisplatin).
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number of DSBs could also have been caused by apoptosis. In
cells undergoing apoptosis, PARP1 is cleaved from a full-length
116 kDa protein into 89 and 24 kDa polypeptides by caspase-
3.21 These PARP1 cleavage fragments were not observed when
cells were treated with HU plus CU1 or CU2, indicating that
the effects we observed on H2AX and KAP1 phosphorylation
were not due to apoptosis and, instead, were likely due to the
compounds inducing a defect in the FA pathway (Figure 3a).
To investigate if the compounds were affecting more
widespread ubiquitylation events in the cell, the monoubiqui-
tylation status of histone H2A was assessed (mUb-H2A; Figure
3a). The polycomb repressive complex 1 (PRC1) mediates
ubiquitylation of histone H2A through its E3 ligase subunits,
RING1A and BMI1, in combination with UBE2D3.22 In
addition, the total level of monoubiquitinylated and poly-
ubiquitinylated conjugates in the cell was assessed by
immunoblotting of cell extracts with the FK2 antibody,
which recognizes conjugated ubiquitin (Figure 3e). mUb-
H2A and total protein ubiquitylation levels were not detectably
affected in the presence of CU1 or CU2, suggesting that these
compounds are not pan-ubiquitylation inhibitors.
In response to DNA damage, mUb-FANCD2 accumulates at
sites of DNA lesions to form foci, promote DNA-damage
sensing, activate cell-cycle checkpoints, and promote DNA
repair.23 Therefore, we employed high-throughput high-
content indirect immunofluorescence studies to examine the
effect of CU1 and CU2 on mUb-FANCD2 focus formation.
The experimental format used was similar to the immunoblot-
based experiments, excepting that, following treatment with
HU (2.5 mM for 8 h) or cisplatin (10 μM for 8 h), cells were
fixed, permeabilized and stained with specific FANCD2
primary and fluorescent secondary antibodies. In addition to
monitoring mUb-FANCD2 foci, γH2AX was evaluated as a
marker of DNA damage induction, and cell nuclei were
visualized by 4′,6-diamidino-2-phenylindole (DAPI) staining.
We observed a clear reduction in the number of FANCD2 foci
per cell in CU1- or CU2-treated cells in the presence of HU or
cisplatin, relative to HU or cisplatin alone (Figures 4a, 4b, and
4c). These observations are in accord with the immunoblot-
based experiments wherein reductions in mUb-FANCD2 were
observed (Figure 3a). Although γH2AX levels appear to be
higher in the HU-treated cells (Figure 3a), as was the case in
the immunoblot assay, the p-value of this increase did not pass
the statistical threshold (p < 0.05). No such apparent increase
was observed in the case of cisplatin treatment (see Figure S7
in the Supporting Information). The quantitative results
namely, no reduction in γH2AX positive cells treated with
CU1 or CU2 in combination with HU or cisplatinare
consistent with the cell cycle analyses indicating that CU1 or
CU2 lead to no reduction in S-phase indices.
Finally, to investigate if CU1 and CU2 could sensitize cells
to a more clinically relevant chemotherapeutic agent,
quantitative live cell analyses were performed using the
IncuCyte platform. As the FA pathway is involved in the
repair of ICLs, cells were treated with the ICL-inducing
chemotherapeutic drug, carboplatin. For this experiment,
U2OS cells were seeded at a relatively low (<10%) density
and preincubated with CU1 or CU2 for 1 h. Carboplatin was
then added to the cells and images were taken every 6 h for 8
days in order to monitor growth and proliferation of the cells.
Although 500 μM CU2 was used in the immunoblot- and
immunofluorescence-based experiments, this concentration
was found to be cytotoxic/cytostatic upon longer cellular
exposures. In contrast, CU2 at 250 μM had a minimal effect on
cell growth, with cells reaching 100% confluency after 6 days, a
similar situation to when the cell line was treated with DMSO
alone (Figure 4d). The addition of 15 μM carboplatin to
DMSO-treated cells led to a clear reduction in proliferation
rate, and, after 8 days, the cells had still not reached 100%
confluency. The combination of 250 μM CU2 with 15 μM
carboplatin led to an even more pronounced decrease in cell
proliferation/growth, with the cells being <50% confluent after
8 days (Figure 4d; as shown in Figure S8 in the Supporting
Information, while the effect of CU1 was also examined, it was
found to strongly inhibit cell growth at concentrations of >50
μM and the combined effect of 50 μM CU1 with 15 μM
carboplatin was far less pronounced than that observed for
CU2).
In summary, the small-molecule screening campaign and
follow-up studies described herein represent a potential
starting point for the development of a chemical probe or
therapeutic agent targeting the FA pathway. One of the
compounds identified, CU2, exhibits promising selectivity in
biochemical ubiquitylation assays and also demonstrated
activity against the FA pathway in cells. Further work will be
necessary to elucidate the precise nature of the protein or
protein complex to which CU2 binds. Given the relatively low
molecular weight (357 Da) of CU2, there is certainly scope to
improve its cellular potency and target selectivity through
chemical synthesis. CU1 represents a less-attractive starting
point, in view of the cytotoxicity that we observed. A more
potent inhibitor of the FA pathway could find clinical
application in sensitizing cancer cells to DNA cross-linking
agents (such as carboplatin or mitomycin C). A selective FA
pathway inhibitor could also be utilized in the identification
and exploitation of synthetic lethal interactions in cancer cells
with certain genetic backgrounds.24
■ MATERIALS AND METHODS
Detailed methods are described in the Supporting Information.
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